

Remarks/Arguments:

Claims 1, 2 and 6-10 are pending in the instant application after the current amendment. Claim 1 has been amended as described below and claims 11 and 12 have been canceled.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicant notes the election/restriction requirement has been made final.

The claims have been amended to delete those embodiments drawn to the nonelected invention, i.e. those embodiments wherein $Y = CR^6$.

In the interest of expediting prosecution, claims 11 and 12 have been deleted thereby obviating the 35 USC 112, first paragraph, rejection with respect thereto.

Applicant has amended claim 1 to contain proper Markush groups. It is believed claim 1 is now consistent with MPEP 2173.05(h).

In view of the foregoing, Applicant believes the application is in condition for allowance, which action is respectfully requested.

Although Applicant believes no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100877-1P US.

Respectfully submitted,
/Carol A. Loeschorn/

Name: Carol A. Loeschorn
Dated: October 8, 2008
Reg. No.: 35,590
Phone No.: 781-839-4002
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 02451